<DOC>
	<DOCNO>NCT00000773</DOCNO>
	<brief_summary>To determine safety , tolerance , pharmacokinetics new improve microparticulate suspension formulation atovaquone administer one two dose level ( per 09/30/94 amendment , third dose level add ) daily 12 day HIV-infected perinatally expose ( per 8/9/95 amendment ) infants child risk develop Pneumocystis carinii pneumonia ( PCP ) . Atovaquone show prophylactic potential adult treatment PCP poorly absorb tablet form . To improve bioavailability atovaquone , new formulation prepare microparticulate suspension . Since study adult demonstrate substantial safety drug , evaluation child pursue .</brief_summary>
	<brief_title>Phase I Safety Pharmacokinetics Study Microparticulate Atovaquone ( m-Atovaquone ; 566C80 ) HIV-Infected Perinatally Exposed Infants Children</brief_title>
	<detailed_description>Atovaquone show prophylactic potential adult treatment PCP poorly absorb tablet form . To improve bioavailability atovaquone , new formulation prepare microparticulate suspension . Since study adult demonstrate substantial safety drug , evaluation child pursue . Three cohort four patient ( age 2-12 year , 3 month le 2 year , 1 month less 3 month ) receive atovaquone daily 12 day . The old age group treat first . In absence unacceptable toxicity , dose atovaquone escalated subsequent 4-patient cohort represent age stratification ( per 9/30/94 amendment ) separate 4-patient cohort age 3 month le 2 year . If two four patient give cohort experience unacceptable toxicity initial dose , two additional patient age range enter . Blood sample draw pharmacokinetic evaluation . Patients follow day 24 . Per 9/30/94 amendment , patient age 3 month le 2 year age receive one low dos may re-enroll high dose cohort 1-month washout .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) . Dideoxycytidine ( zalcitabine ; ddC ) . Didanosine ( ddI ) . Nonaminoglycoside , nonmacrolide , nonsulfonamide antibiotic . Factor VIII . IVIG . Patients must : AIDS , document HIV infection , perinatal exposure HIV , risk develop PCP . Normal EKG chest radiograph . No blood protein urinalysis . Consent parent guardian . Prior Medication : Allowed : Prophylactic TMP/SMX give less 3 day prior study entry . Prophylactic aerosolized pentamidine ( single intravenous dose 4.0 mg/kg pentamidine ) give less 7 day prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Anticipated organ system laboratory abnormality ( immune system abnormality ) primary disease treatment study . Acute chronic infection require treatment study . NOTE : Thrush herpes labialis allow condition require treatment . Diarrhea vomit . Concurrent Medication : Excluded : Trimethoprim/sulfamethoxazole . Sulfadoxine pyrimethamine ( Fansidar ) . Primaquine . Aspirin . Amphotericin B. Aminoglycoside antibiotic . Sulfonamides . Dapsone . Benzodiazepines . Rifampin . Erythromycin , clarithromycin , azithromycin . Digitalis . Paraaminosalicylic acid ( PAS ) . Isoniazid . Anticoagulants . Any investigational therapy . Patients follow prior condition exclude : History G6PD deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Biological Availability</keyword>
	<keyword>atovaquone</keyword>
</DOC>